Eric Rowinsky

Primrose Therapeutics, Inc. is a private company based in New York, NY. The company was founded by Eric K. Rowinsky, Philip Frost.

Operates as a biopharmaceutical company, which develops monoclonal antibodies for cancer

Functions as a College/University

Conducts research projects & awards grants for cancer research

Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments.

Provides advanced technology solutions and services for oncology drugs

Develops pharmaceutical products

Functions as a College/University

Develops and markets dietary supplements and ingredients for functional food based on tropical plants

Maxwell Asset Management manages the Maxwell Biotech Venture Fund. The fund focuses on investments in the biotechnology and pharmaceutical sectors with emphasis on therapeutics, industrial biotechnology and agricultural/veterinary applications. Within the therapeutics industry, the Fund focuses on investments in clinical areas of oncology, diseases of the central nervous system and metabolic disorders. The Fund invests in the application of biotechnology for industrial purposes including the production of biofuels and industrial reagents. In addition, the Fund invests in the application of biotechnology to strategically important agricultural products, such as plant growth promoters, crop protectors and animal health products. The Fund invests in public and private companies in North America, Europe and other parts of the world. Maxwell looks for companies: (1) that are developing products and technologies that are synergistic with the Fund's existing portfolio companies (2) with products that can benefit from testing in Russian clinical trial centers and (3) are interested in commercializing innovative therapeutics in the Russian market. The Maxwell Biotech Venture Fund's primary goal is to invest in Russian-based companies that are developing innovative products and technologies for the domestic and global markets. Maxwell also works with and invests in Western companies when they can help them advance their products along the development path, bring innovative products to the Russian market and generate superior return on investment. Typical investments range from $1 million to $10 million per company, depending on the stage of the company and its products. Maxwell is open to syndication with other venture firms. They place priority on investments that are likely to lead to a financial exit within 5 years.

Discovers, develops, manufactures and supplies pharmaceutical products

Discovers and develops drugs

Operates as a biotechnology company which develops oncology therapeutics

Develops bio-pharmaceutical drugs

Provides pharmaceutical drug discovery and development services

Functions as a College/University

Functions as a College/University

Functions as a College/University

Discovers and develops drugs for cancer

Provides pharma data analytics solutions

Specializes in custom software solutions, web design, mobile applications, media services, graphic design, digital and print marketing

Manufactures pharmaceutical products

Provides biopharmaceutical companies with an alternative mechanism for accelerating product development

Operates as a clinical-stage biopharmaceutical company which develops and commercializes therapies to address critical unmet medical needs

Functions as a College/University

Operates as a biotechnology company

Part of Hummingbird Bioscience Pte Ltd., Hummingbird Bioscience, Inc. is a clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes. The company is based in Houston, TX. The company was founded in 2015 by Jerome Boyd-Kirkup, Piers Ingram. Piers Ingram has been the CEO of the company since 2015.